1. Capacity expansion and upgradation of manufacturing facilities 2. Establishment of a new R&D Centre 3. Repayment / prepayment of certain outstanding borrowings 4. Working capital requirements 5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) and 6. General corporate purposes